1 recruiting, 1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Christoph Aufricht: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank Registry - Focal Segmental Glomerulosclerosis, Proteinuria | Recruiting | Christoph Aufricht | 100 | 2023-01-01 | 2023-12-08 | |
| Safety and Efficacy of the Addition of Alanyl-Glutamine-Dipeptide to Dialysis Solution in Peritoneal Dialysis Dipeptiven (Alanyl-glutamine-dipeptide) - End Stage Renal Disease | Phase 1 / Phase 2 | Terminated | Christoph Aufricht | 25 | 2011-04-01 | 2015-09-11 |
Glomerulosclerosis, Focal Segmental (1) · Kidney Failure, Chronic (1) · Nephrotic Syndrome (1) · Proteinuria (1)
Registries (1) · alanylglutamine (1)
Austria (2)